Skip to main content
Top
Published in: Pathology & Oncology Research 3/2008

01-09-2008 | Brief Communication

Prolonged Survival Using Anti-CD20 Combined Chemotherapy in Primary Prostatic Intravascular Large B-cell Lymphoma

Authors: Judit Csomor, Ilona Kaszás, Balázs Kollár, László Pajor, Zsolt Egyházi, Sándor Fekete, Miklós Egyed, Botond Timár

Published in: Pathology & Oncology Research | Issue 3/2008

Login to get access

Abstract

Here we report a case of a 73-year-old man with primary intravascular large B-cell lymphoma localized to the prostate. Total prostatectomy was performed due to a benign adenoma suggested by ultrasonography. The diagnosis of IVLBL was obtained incidentally from the prostatectomy specimen. Eight months after the initial R-CHOP chemotherapy a relapse was detected in the left inguinal lymph node, where histologic examination revealed common diffuse large B-cell lymphoma with minimal intravascular component. The second complete remission was achieved by R-IEV therapy. Five months later a second relapse occurred and the patient died in the widespread disease and pneumonia. Primary prostate IVLBL is extremely uncommon; to date only four cases have been described. This is a well documented case, where we also confirmed that the initial primary IVLBL and the secondary lymph node involvement are clonally related. Successful treatment depends on early diagnosis of IVLBL, aggressive chemotherapy and the fact that IVLBL should be considered as a generalized disease in spite of negative staging results.
Literature
1.
go back to reference Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds) (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds) (2001) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon
2.
go back to reference Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A et al (2004) Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol 127(2):173–183CrossRefPubMed Ferreri AJ, Campo E, Seymour JF, Willemze R, Ilariucci F, Ambrosetti A et al (2004) Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br J Haematol 127(2):173–183CrossRefPubMed
3.
go back to reference Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B (1998) Malignant lymphoma involving the prostate: report of 62 cases. Cancer 83(4):732–738CrossRefPubMed Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B (1998) Malignant lymphoma involving the prostate: report of 62 cases. Cancer 83(4):732–738CrossRefPubMed
4.
go back to reference Chu PG, Huang Q, Weiss LM (2005) Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am J Surg Pathol 29(5):693–699CrossRefPubMed Chu PG, Huang Q, Weiss LM (2005) Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy: a study of 29 cases. Am J Surg Pathol 29(5):693–699CrossRefPubMed
5.
go back to reference Yin XR, Liu H, Chen HQ (2005) Intravascular lymphomatosis of the prostate gland. Zhonghua Bing Li Xue Za Zhi 34(3):189–190, ChinesePubMed Yin XR, Liu H, Chen HQ (2005) Intravascular lymphomatosis of the prostate gland. Zhonghua Bing Li Xue Za Zhi 34(3):189–190, ChinesePubMed
6.
go back to reference Alfaro J, Espinoza A, Manŕiquez M, Moyano L, González N, Larrondo M, Figueroa G (2004) Intravascular lymphoma treated with anti CD20 monoclonal antibodies. Report of one case. Rev Med Chil 132(11):1403–1406, SpanishPubMed Alfaro J, Espinoza A, Manŕiquez M, Moyano L, González N, Larrondo M, Figueroa G (2004) Intravascular lymphoma treated with anti CD20 monoclonal antibodies. Report of one case. Rev Med Chil 132(11):1403–1406, SpanishPubMed
7.
go back to reference Quintini G, Barbera V, Franco V, Florena AM, Spadola V, Mariani G (2003) Uncommon presentations of non-Hodgkin’s lymphoma: case 1. Intravascular large B-cell lymphoma: diagnosis on prostate biopsy. J Clin Oncol 21(3):564–565CrossRefPubMed Quintini G, Barbera V, Franco V, Florena AM, Spadola V, Mariani G (2003) Uncommon presentations of non-Hodgkin’s lymphoma: case 1. Intravascular large B-cell lymphoma: diagnosis on prostate biopsy. J Clin Oncol 21(3):564–565CrossRefPubMed
8.
9.
go back to reference Ponzoni M, Arrigoni G, Gould VE, Del Curto B, Maggioni M, Scapinello A et al (2000) Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 31(2):220–226CrossRefPubMed Ponzoni M, Arrigoni G, Gould VE, Del Curto B, Maggioni M, Scapinello A et al (2000) Lack of CD 29 (beta1 integrin) and CD 54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 31(2):220–226CrossRefPubMed
10.
go back to reference Kishi Y, Kami M, Kusumi E, Mineyama T, Kato D, Hamaki T et al (2004) Prostatic acid phosphatase: a possible diagnostic marker of intravascular large B-cell lymphoma. Haematologica 89(5):ECR13PubMed Kishi Y, Kami M, Kusumi E, Mineyama T, Kato D, Hamaki T et al (2004) Prostatic acid phosphatase: a possible diagnostic marker of intravascular large B-cell lymphoma. Haematologica 89(5):ECR13PubMed
11.
go back to reference Odawara J, Asada N, Aoki T, Yamakura M, Takeuchi M, Ohuchi T et al (2007) 18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma. Br J Haematol 136(5):684CrossRefPubMed Odawara J, Asada N, Aoki T, Yamakura M, Takeuchi M, Ohuchi T et al (2007) 18F-Fluorodeoxyglucose positron emission tomography for evaluation of intravascular large B-cell lymphoma. Br J Haematol 136(5):684CrossRefPubMed
12.
go back to reference Bouzani M, Karmiris T, Rontogianni D, Delimpassi S, Apostolidis J, Mpakiri M et al (2006) Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy. Oncologist 11(8):923–928CrossRefPubMed Bouzani M, Karmiris T, Rontogianni D, Delimpassi S, Apostolidis J, Mpakiri M et al (2006) Disseminated intravascular B-cell lymphoma: clinicopathological features and outcome of three cases treated with anthracycline-based immunochemotherapy. Oncologist 11(8):923–928CrossRefPubMed
13.
go back to reference Ohno T, Sakamoto T, Mizumoto C, Miyoshi T, Ueda M, Takeoka T et al. (2006) Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy. Int J Hematol 84(1):74–78CrossRefPubMed Ohno T, Sakamoto T, Mizumoto C, Miyoshi T, Ueda M, Takeoka T et al. (2006) Leukemic and meningeal relapse of CD5+ intravascular large B-cell lymphoma with down-modulation of CD20 after rituximab therapy. Int J Hematol 84(1):74–78CrossRefPubMed
Metadata
Title
Prolonged Survival Using Anti-CD20 Combined Chemotherapy in Primary Prostatic Intravascular Large B-cell Lymphoma
Authors
Judit Csomor
Ilona Kaszás
Balázs Kollár
László Pajor
Zsolt Egyházi
Sándor Fekete
Miklós Egyed
Botond Timár
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2008
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9051-y

Other articles of this Issue 3/2008

Pathology & Oncology Research 3/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine